BioNotebook: Amarin, Sucampo/R-Tech, Questcor, Avanir
This article was originally published in Scrip
Amarin cuts half of staff; Sucampo partner R-Tech starts Phase III study in Japan; Questcor begins second Acthar Phase II study this year; and Avanir initiates Phase II Parkinson's study.
You may also be interested in...
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.